Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting
October 04 2023 - 6:59AM
Business Wire
Presentations Will Feature Blink® Triple
Care Lubricating Dry Eye Drops, MIEBO™ (perfluorohexyloctane
ophthalmic solution) and Bausch + Lomb INFUSE® Multifocal
Lenses
Company Will Host Seven Educational
Events
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye
health company dedicated to helping people see better to live
better, today announced one podium presentation and four poster
presentations during the American Academy of Optometry (AAOpt)
annual meeting, which will take place in New Orleans Oct. 11-14,
2023.
The podium presentation will highlight the results of a
prospective, multi-center study that evaluated key clinical dry eye
disease (DED) findings in patients using Blink Triple Care Dry Eye
Lubricating Eye Drops. Bausch + Lomb acquired the Blink brand of
eye drops for dry eyes and contacts from Johnson & Johnson
Vision earlier this year.
Two poster presentations will include data on the newly launched
MIEBO prescription eye drops, including an evaluation of the
distribution and retention of MIEBO on the human eye and an
analysis of the effect of MIEBO on fluorescein staining across all
regions of the cornea. Additionally, two posters will feature data
on Bausch + Lomb INFUSE Multifocal silicone hydrogel daily
disposable contact lenses, which launched in June, including an
evaluation of the lens’ clinical performance and an assessment of
patient responses to the lens.
Bausch + Lomb will also host several educational events during
the meeting featuring MIEBO eye drops, the new LUMIFY EYE
ILLUMINATIONS™ product line, LOTEMAX® SM (loteprednol etabonate
ophthalmic gel) 0.38% and VYZULTA® (latanoprostene bunod ophthalmic
solution) 0.024%. Another educational event will highlight
practical patient cases using products from across the company’s
consumer, vision care and pharmaceutical portfolios.
The Bausch + Lomb schedule at AAOpt:
Podium Presentation
- “Clinical Dry Eye Findings in Patients Using a Novel
Lipid-Containing Eye Drop.” Joshi et al.
Poster Presentations
- “Clinical Performance of a Novel Daily Disposable Silicone
Hydrogel Multifocal Contact Lens.” Schafer et al.
- “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces
Corneal Staining Across All Regions of the Cornea.” Fahmy et
al.
- “Presbyopic Patient Assessment of a New Daily Disposable
Silicone Hydrogel Multifocal Contact Lens.” Rah et al.
- “Visualization of MIEBO, an Eye Drop for Dry Eye Disease, on
the Human Ocular Surface Using Infrared Emisivity.” Borchman et
al.
Featured Educational Events
Wednesday, October 11
- “Industry Innovation Lunch and Learn” 12-12:55 p.m. CT at the
Ernest N. Morial Convention Center (900 Convention Center Blvd.,
New Orleans; Room R06, second floor) Gina Wesley, O.D., John
Womack, O.D., and Doug DeVries, O.D., will share practical patient
cases using products from across the Bausch + Lomb consumer, vision
care and pharmaceutical portfolios.
- “Showcasing Inflammation and IOP Control” 6:45 p.m. CT at
Palace Café (605 Canal Street, New Orleans; room Fleur de Lis)
Michael Chaglasian, O.D., and Nora Cothran, O.D. will discuss the
benefits of using LOTEMAX® SM (loteprednol etabonate ophthalmic
gel), 0.38%, and VYZULTA® (latanoprostene bunod ophthalmic
solution), 0.024%. Register in advance.
Thursday, October 12
- “Introducing New LUMIFY EYE ILLUMINATIONS” 8:00-8:45 a.m. CT at
Hilton New Orleans Riverside (Two Poydras Street, New Orleans; room
Royal) Join Gina Wesley, O.D., to discover LUMIFY EYE
ILLUMINATIONS, a new specialty eye care line.
- “Innovations in Inflammation and IOP Control” 8:00-8:45 a.m. CT
at Hilton New Orleans Riverside (Two Poydras Street, New Orleans;
room Camp) Derek Cunningham, O.D., will discuss the benefits of
using LOTEMAX® SM (loteprednol etabonate ophthalmic gel), 0.38%,
and VYZULTA® (latanoprostene bunod ophthalmic solution),
0.024%.
- “Fighting the Battle in the Rx Treatment of Evaporative Dry Eye
Disease: Introducing MIEBO (Perfluorohexyloctane Ophthalmic
Solution)” 6:00 p.m. CT at the National World War II Museum (1043
Magazine Street, US Freedom Pavilion, New Orleans) Learn about
MIEBO, the first and only prescription eye drop that directly
targets tear evaporation, as well as the results of the MIEBO
pivotal phase 3 studies. Register in advance.
Friday, October 13
- “MIEBO (perfluorohexyloctane ophthalmic solution): A Newly
Approved Product” 8:00-8:45 a.m. CT at Hilton New Orleans Riverside
Hotel (Two Poydras Street, New Orleans; room Canal) Tear
evaporation is the leading cause of dry eye disease. Join James
Deom, O.D., to learn more about MIEBO, the first and only
prescription eye drop that directly addresses tear
evaporation.
- “A New Orleans Nightcap with LUMIFY EYE ILLUMINATIONS”
8:30-10:30 p.m. CT at the Gallery Venue (755 Tchoupitoulas Street,
New Orleans) Celebrate the launch of LUMIFY EYE ILLUMINATIONS and
learn about these new clinically proven products from Selina McGee,
O.D. Register in advance.
Important Safety Information for MIEBO
INDICATION
MIEBO™ (perfluorohexyloctane ophthalmic solution) is used to
treat the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- Patients should remove contact lenses before using MIEBO™ and
wait for at least 30 minutes before reinserting.
- It is important for patients to use MIEBO exactly as
prescribed.
- It is not known if MIEBO™ is safe and effective in children
under the age of 18.
- The most common eye side effect seen in studies was blurred
vision (1% to 3 % of patients reported blurred vision and eye
redness).
Click here for full Prescribing Information for
MIEBO.
Important Safety Information for LOTEMAX SM
INDICATION
LOTEMAX SM (loteprednol etabonate ophthalmic gel) 0.38% is a
corticosteroid indicated for the treatment of post-operative
inflammation and pain following ocular surgery.
IMPORTANT SAFETY INFORMATION
- LOTEMAX SM, as with other ophthalmic corticosteroids, is
contraindicated in most viral diseases of the cornea and
conjunctiva including epithelial herpes simplex keratitis
(dendritic keratitis), vaccinia, and varicella, and also in
mycobacterial infection of the eye and fungal diseases of ocular
structures.
- Prolonged use of corticosteroids may result in glaucoma with
damage to the optic nerve, defects in visual acuity and fields of
vision. Steroids should be used with caution in the presence of
glaucoma. If LOTEMAX SM is used for 10 days or longer, IOP should
be monitored.
- Use of corticosteroids may result in posterior subcapsular
cataract formation.
- The use of steroids after cataract surgery may delay healing
and increase the incidence of bleb formation. In those with
diseases causing thinning of the cornea or sclera, perforations
have been known to occur with the use of topical steroids. The
initial prescription and renewal of the medication order should be
made by a physician only after examination of the patient with the
aid of magnification such as slit lamp biomicroscopy and, where
appropriate, fluorescein staining.
- Prolonged use of corticosteroids may suppress the host response
and thus increase the hazard of secondary ocular infections. In
acute purulent conditions, steroids may mask infection or enhance
existing infections.
- Employment of a corticosteroid medication in the treatment of
patients with a history of herpes simplex requires great caution.
Use of ocular steroids may prolong the course and may exacerbate
the severity of many viral infections of the eye (including herpes
simplex).
- Fungal infections of the cornea are particularly prone to
develop coincidentally with long-term local steroid application.
Fungus invasion must be considered in any persistent corneal
ulceration where a steroid has been used or is in use. Fungal
cultures should be taken when appropriate.
- Contact lenses should not be worn when the eyes are
inflamed.
- There were no treatment-emergent adverse drug reactions that
occurred in more than 1% of subjects in the three times daily group
compared to vehicle.
Click here for full Prescribing Information for
LOTEMAX SM.
Important Safety Information for VYZULTA
INDICATION
VYZULTA (latanoprostene bunod ophthalmic solution) 0.024% is
indicated for the reduction of intraocular pressure (IOP) in
patients with open-angle glaucoma or ocular hypertension.
IMPORTANT SAFETY INFORMATION
- Increased pigmentation of the iris and periorbital tissue
(eyelid) can occur. Iris pigmentation is likely to be
permanent
- Gradual changes to eyelashes, including increased length,
increased thickness, and number of eyelashes, may occur. These
changes are usually reversible upon treatment discontinuation
- Use with caution in patients with a history of intraocular
inflammation (iritis/uveitis). VYZULTA should generally not be used
in patients with active intraocular inflammation
- Macular edema, including cystoid macular edema, has been
reported during treatment with prostaglandin analogs. Use with
caution in aphakic patients, in pseudophakic patients with a torn
posterior lens capsule, or in patients with known risk factors for
macular edema
- There have been reports of bacterial keratitis associated with
the use of multiple-dose containers of topical ophthalmic products
that were inadvertently contaminated by patients
- Contact lenses should be removed prior to the administration of
VYZULTA and may be reinserted 15 minutes after administration
- Most common ocular adverse reactions with incidence ≥2% are
conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%),
and instillation site pain (2%)
Please click here for full Prescribing
Information.
Patients are encouraged to report negative side effects of
these prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift
of sight for millions of people around the world – from the moment
of birth through every phase of life. Its comprehensive portfolio
of more than 400 products includes contact lenses, lens care
products, eye care products, ophthalmic pharmaceuticals,
over-the-counter products and ophthalmic surgical devices and
instruments. Founded in 1853, Bausch + Lomb has a significant
global research and development, manufacturing and commercial
footprint with approximately 13,000 employees and a presence in
nearly 100 countries. Bausch + Lomb is headquartered in Vaughan,
Ontario with corporate offices in Bridgewater, New Jersey. For more
information, visit www.bausch.com and connect with us on Twitter,
LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which
may generally be identified by the use of the words “anticipates,”
“hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,”
“may,” “believes,” “estimates,” “potential,” “target,” or
“continue” and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks and uncertainties discussed in
Bausch + Lomb’s filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch + Lomb undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
© 2023 Bausch + Lomb.
MTB.0285.USA.23
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231004560490/en/
Media Contact: Kristy Marks kristy.marks@bausch.com (908)
927-0683
Investor Contact: George Gadkowski
george.gadkowski@bausch.com (877) 354-3705 (toll free) (908)
927-0735
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Apr 2024 to May 2024
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From May 2023 to May 2024